AstraZeneca Seeks To Shield Seroquel Sales Rep Notes, Study Reports In Pending Injury Cases
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca says internal company information should not be released before personal injury cases go to trial.
You may also be interested in...
AstraZeneca Internal Seroquel Documents Cite Cherry-Picking, Burying Data
AstraZeneca agreed to unseal internal communications in Seroquel product liability litigation discussing risks associated with the drug.
AstraZeneca Internal Seroquel Documents Cite Cherry-Picking, Burying Data
AstraZeneca agreed to unseal internal communications in Seroquel product liability litigation discussing risks associated with the drug.
Lilly $1.4B Zyprexa Settlement Is Biggest Ever, But Some State Claims Still Pending
Criminal and civil penalties stem from a “commitment to off-label marketing” with 2,000 sales reps, U.S. Attorney Magid says.